Navigation Links
BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
Date:7/9/2009

NEWARK, N.J., July 9 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science company announced today that at ATS Labs, using a Quantitative Disk Carrier test starting with 5.5 million Clostridium Difficile (C.diff) spores, BioNeutral's Ygiene(TM) Hospital Grade antimicrobial delivered an amazing 99.9997% kill.

Clostridium Difficile, an extremely dangerous and difficult to eradicate spore, is associated with hospital acquired infections which results in diverted health care providers' efforts, millions of dollars in extra health care expenses, and tens of thousands of unnecessary deaths annually in the United States alone. The best high powered antimicrobial currently used in hospitals as a disinfectant is based upon quaternary ammonium compounds which are ineffective at eradicating Clostridium Difficile spores, resulting in a serious unmet need in the health care arena.

According to Wyeth, a global leader in pharmaceuticals and consumer healthcare products, in the United States, hospital-acquired infections alone afflict nearly 2 million patients and kill approximately 90,000 people annually, more than diabetes or influenza/pneumonia.

About 70% of these hospital-acquired infections are resistant to at least one drug and nosocomial infections, which costs U.S. society between $4 billion and $5 billion annually.

Dr. Andrew Kielbania, Chief Scientist at BioNeutral, stated, "At BioNeutral we have raised the bar in terms of developing superior antimicrobial formulations. Clostridium Difficile spores represents a significant health threat and also is one of the most difficult to eradicate spores in the heath care area. These impressive independent lab pre-testing results not only validate our internal results but also give us great confidence that our ongoing EPA registration of our Ygiene(TM) Hospital Grade Antimicrobial will be successful with an ultimate 100% total kill."

Stephen J. Browand, BioNeutral Group Inc. CEO stated, "We are very encouraged by these first pre-testing results of our Hospital Grade formulation that will undoubtedly save many lives and protect countless others from being exposed to a hospital acquired infection. To have a non-toxic, non-corrosive disinfectant that can kill the very resilient C.diff spore is truly an amazing scientific breakthrough. The fact that it is also environmentally friendly makes it a groundbreaking event."

To complement its internal Ygiene(TM) research and development efforts, BioNeutral frequently uses highly recognized independent laboratories such as ATS Labs of Eagan, MN. In developing superior Ygiene(TM) antimicrobial formulations BioNeutral also uses testing protocols which place an extra and extreme demand on the antimicrobial formulation.

About ATS Labs: ATS Labs is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the United States, Canada and worldwide.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. BioNeutral has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com.

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how BioNeutral's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the BioNeutral's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Contact Information

    BioNeutral Group Inc.
    Stephen J. Browand, President and CEO
    steve@bioneutralgroup.com

    Investor Relations
    Aimee Boutcher
    973 239-2878
    aboutcher@aol.com


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
2. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
3. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
4. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
5. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
6. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
7. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
8. New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More
9. TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower
10. Vancouver General Hospital is the First Canadian Institution to Implement Copan WASP(R): Walk-Away Specimen Processor
11. Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ... December 31, 2015. --> --> ... net loss of $29.3 million, or $0.34 loss per share, compared ... share for the same period in 2014. For the year ended ... million, or $1.05 loss per share, as compared to a net ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... 2016 --> ... (OTCQB: PSID), a life sciences company focused on ... subsidiary, which markets the Caregiver® FDA-cleared non-contact thermometer, ... January 2016, including entering into agreements with five ... growth, and establishing several near-term pipeline opportunities. ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
Breaking Biology Technology:
(Date:2/9/2016)... AWRE ), a leading supplier of biometrics software and services, ... December 31, 2015.  --> --> ... an increase of 61% compared to $4.3 million in the same ... was $2.6 million compared to $0.2 million in the fourth quarter ... Higher revenue and operating income in the fourth quarter of this ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/3/2016)... , February 3, 2016 ... new market research report "Automated Fingerprint Identification System Market ... Latent Search), Application (Banking & Finance, Government, Healthcare, and ... by MarketsandMarkets, the market is expected to be worth ... of 21.0% between 2015 and 2020. The transformation and ...
Breaking Biology News(10 mins):